{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T09:47:38Z","timestamp":1782812858739,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11864-009-0094-4","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T08:40:07Z","timestamp":1240389607000},"page":"44-53","source":"Crossref","is-referenced-by-count":23,"title":["Worldwide Impact of the Human Papillomavirus Vaccine"],"prefix":"10.1007","volume":"10","author":[{"given":"Amy A.","family":"Hakim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri A.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,23]]},"reference":[{"issue":"Early Release","key":"94_CR1","first-page":"1","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","unstructured":"Centers for Disease Control and Prevention: Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007, 56(Early Release): 1\u201324.","journal-title":"MMWR"},{"key":"94_CR2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/00006250-200504000-00056","volume":"105","author":"ACOG Practice Bulletin: Practice Bulletin","year":"2005","unstructured":"ACOG Practice Bulletin: Practice Bulletin: Clinical management guidelines for obstetricians-gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005, 105:905\u2013918.","journal-title":"Obstet Gynecol"},{"key":"94_CR3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55, 74\u2013108 (2005). doi: 10.3322\/canjclin.55.2.74","journal-title":"CA Cancer J Clin"},{"key":"94_CR4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","volume":"23","author":"SR Pagliusi","year":"2004","unstructured":"Pagliusi SR, Teresa Aguado M: Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23, 569\u2013578 (2004). doi: 10.1016\/j.vaccine.2004.07.046","journal-title":"Vaccine"},{"issue":"19","key":"94_CR5","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMp078053","volume":"356","author":"JM Agosti","year":"2007","unstructured":"Agosti JM, Goldie SJ: Introducing HPV vaccine in developing countries\u2014key challenges and issues. N Engl J Med 356(19), 1908\u20131910 (2007)","journal-title":"N Engl J Med"},{"key":"94_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","volume":"55","author":"FX Bosch","year":"2002","unstructured":"Bosch FX, Lorncz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papilloma virus in cervical cancer. J Clin Pathol 55, 244\u2013265 (2002)","journal-title":"J Clin Pathol"},{"key":"94_CR7","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"Koutsky LA, Ault KA, Wheeler CM et\u00a0al.: A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 347, 1645\u20131651 (2002)","journal-title":"N Engl J Med"},{"key":"94_CR8","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ygyno.2008.05.011","volume":"110","author":"J-M Bayas","year":"2008","unstructured":"Bayas J-M, Costas L, Munoz A: Cervical cancer indications, efficacy, and side effects. Gynecol Oncol 110, S11\u2013S14 (2008)","journal-title":"Gynecol Oncol"},{"issue":"7","key":"94_CR9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","volume":"7","author":"S De Sanjose","year":"2007","unstructured":"De Sanjose S, Diaz M, Catellsague X et\u00a0al.: Worldwide prevalence and genotype distribution of cervical human papilloma virus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7), 453\u2013459 (2007)","journal-title":"Lancet Infect Dis"},{"key":"94_CR10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T et\u00a0al.: Cancer statistics, 2004. CA Cancer J Clin 54, 8\u201329 (2004)","journal-title":"CA Cancer J Clin"},{"key":"94_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1054\/bjoc.2001.1845","volume":"84","author":"C Clavel","year":"2001","unstructured":"Clavel C, Masure M, Bory JP et\u00a0al.: Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84, 48\u201355 (2001)","journal-title":"Br J Cancer"},{"key":"94_CR12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/(SICI)1097-0142(19990425)87:2<48::AID-CNCR2>3.0.CO;2-D","volume":"87","author":"ML Hutchison","year":"1999","unstructured":"Hutchison ML, Zahniser DJ, Sherman ME et\u00a0al.: Utility of liquid-based cytology for cervical cancer screening: results of a populations-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 87, 48\u201355 (1999)","journal-title":"Cancer"},{"key":"94_CR13","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ygyno.2008.06.029","volume":"110","author":"DM Harper","year":"2008","unstructured":"Harper DM: Impact with Cervarix on subsequent HPV-16\/18 infection and cervical disease in women 15\u201325\u00a0years of age. Gynecol Oncol 110, S11\u2013S17 (2008)","journal-title":"Gynecol Oncol"},{"key":"94_CR14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM et\u00a0al.: Sustained efficacy up to 4.5\u00a0years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367, 1247\u20131255 (2006)","journal-title":"Lancet"},{"key":"94_CR15","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM et\u00a0al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356, 1928\u20131943 (2007)","journal-title":"N Engl J Med"},{"key":"94_CR16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"Future II Study Group.","year":"2007","unstructured":"Future II Study Group.: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915\u20131927.","journal-title":"N Engl J Med"},{"key":"94_CR17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavanen","year":"2007","unstructured":"Paavanen J, Jenkins D, Bosch FX et\u00a0al.: Efficacy of a prophylactic adjuvant bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase II double-blind, randomized controlled trial. Lancet 369, 2161\u20132170 (2007)","journal-title":"Lancet"},{"key":"94_CR18","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ygyno.2008.01.018","volume":"109","author":"TJ Herzog","year":"2008","unstructured":"Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BM: Initial lessons learned in HPV vaccination. Gynecol Oncol 109, S4\u2013S11 (2008)","journal-title":"Gynecol Oncol"},{"key":"94_CR19","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ygyno.2008.06.027","volume":"110","author":"D Jenkins","year":"2008","unstructured":"Jenkins D: A review of cross-protections against oncogenic HPV by an HPV-16\/18 ASO4-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 110, S18\u2013S25 (2008)","journal-title":"Gynecol Oncol"},{"key":"94_CR20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(01)06523-0","volume":"358","author":"X Castellsague","year":"2001","unstructured":"Castellsague X, Mendez C, Loscertales MP et\u00a0al.: Human papillomavirus genotypes in rural Mozambique. Lancet 358, 1429\u20131430 (2001)","journal-title":"Lancet"},{"key":"94_CR21","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1099\/vir.0.80001-0","volume":"85","author":"P Naucler","year":"2004","unstructured":"Naucler P, Mabotada Costa F, Ljungberg O, Bugalho A, Dillner J: Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol 85, 2189\u20132190 (2004)","journal-title":"J Gen Virol"},{"key":"94_CR22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.bjc.6604462","volume":"99","author":"M Diaz","year":"2008","unstructured":"Diaz M, Kim JJ, Albero G, Clifford G, Bosch FX, Goldie SJ: Health and economic impact of HPV-16 and-18 vaccination and cervical cancer screening in India. Br J Cancer 99, 230\u2013238 (2008)","journal-title":"Br J Cancer"},{"key":"94_CR23","doi-asserted-by":"crossref","first-page":"M43","DOI":"10.1016\/j.vaccine.2008.05.005","volume":"26S","author":"R Sankaranarayanan","year":"2008","unstructured":"Sankaranarayanan R, Bhatla N, Gravitt PE et\u00a0al.: Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka, and Nepal. Vaccine 26S, M43\u2013M52 (2008)","journal-title":"Vaccine"},{"key":"94_CR24","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality, and prevalence worldwide. IARC Cancer Base No 5 Version 2.0. Lyon: IARC Press; 2004."},{"key":"94_CR25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.bjc.6602580","volume":"92","author":"S Franceschi","year":"2005","unstructured":"Franceschi S, Rajkumar R, Snijders PJ et\u00a0al.: Papillomavirus infection in rural women in southern India. Br J Cancer 92, 601\u2013606 (2005)","journal-title":"Br J Cancer"},{"key":"94_CR26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","volume":"366","author":"GM Clifford","year":"2005","unstructured":"Clifford GM, Galluss S, Herrero R et\u00a0al.: Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 366, 991\u2013998 (2005)","journal-title":"Lancet"},{"key":"94_CR27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ijc.21050","volume":"116","author":"R Sankaranarayanan","year":"2005","unstructured":"Sankaranarayanan R, Nene BM, Dinshaw KA et\u00a0al.: A cluster randomized control trial of visual, cytology, and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 116, 617\u2013623 (2005)","journal-title":"Int J Cancer"},{"key":"94_CR28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ijc.20396","volume":"112","author":"R Sankaranarayanan","year":"2004","unstructured":"Sankaranarayanan R, Chatterji R, Shastri SS et\u00a0al.: Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer 112, 341\u2013347 (2004)","journal-title":"Int J Cancer"},{"key":"94_CR29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-5-116","volume":"5","author":"AP Sowjanya","year":"2005","unstructured":"Sowjanya AP, Jain M, Poli UR et\u00a0al.: Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 5, 116 (2005)","journal-title":"BMC Infect Dis"},{"issue":"1","key":"94_CR30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1525-1438.2007.00827.x","volume":"17","author":"P Laikangbam","year":"2007","unstructured":"Laikangbam P, Sengupta S, Bhattacharya P et\u00a0al.: A comparative profile of the prevalence and age distribution of human papilloma virus type 16\/18 infections among three states of India with focus on northeast India. Int J Gynecol Cancer 17(1), 107\u2013117 (2007)","journal-title":"Int J Gynecol Cancer"},{"key":"94_CR31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4038\/cmj.v51i3.1255","volume":"51","author":"R De Silva","year":"2006","unstructured":"De Silva R, Karunaratne K, Mendis LN, Ramesh R, Chow VT: PCR detection and typing of human papilloma virus DNA in squamous carcinoma of the cervix in a cohort of Sri Lankan women. Ceylon Med J 51, 114\u2013117 (2006)","journal-title":"Ceylon Med J"},{"key":"94_CR32","doi-asserted-by":"crossref","first-page":"L96","DOI":"10.1016\/j.vaccine.2008.05.062","volume":"26S","author":"N Munoz","year":"2008","unstructured":"Munoz N, Franco EL, Herrero R et\u00a0al.: Recommendations for Cervical cancer prevention in Latin America and the Caribbean. Vaccine 26S, L96\u2013L107 (2008)","journal-title":"Vaccine"},{"issue":"3","key":"94_CR33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","volume":"121","author":"JS Smith","year":"2007","unstructured":"Smith JS, Lindsay L, Hoots B et\u00a0al.: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3), 621\u2013632 (2007)","journal-title":"Int J Cancer"},{"key":"94_CR34","doi-asserted-by":"crossref","first-page":"M17","DOI":"10.1016\/j.vaccine.2008.06.018","volume":"26S","author":"SJ Goldie","year":"2008","unstructured":"Goldie SJ, Diaz M, Kim S-Y, Levin CE, Van Minh H, Kim JJ: Mathematical models of cervical cancer prevention in the Asia Pacific Region. Vaccine 26S, M17\u2013M29 (2008)","journal-title":"Vaccine"},{"issue":"2","key":"94_CR35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ijc.10936","volume":"104","author":"Th Pham","year":"2003","unstructured":"Pham Th, Nguyen TH, Herrero R et\u00a0al.: Human Papilloma Virus infection among women in South and North Vietnam. Int J Cancer 104(2), 213\u2013220 (2003)","journal-title":"Int J Cancer"},{"issue":"1","key":"94_CR36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","volume":"88","author":"GM Clifford","year":"2003","unstructured":"Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papilloma virus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1), 63\u201373 (2003)","journal-title":"Br J Cancer"},{"issue":"1","key":"94_CR37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.21101\/cejph.b0006","volume":"16","author":"M Grce","year":"2008","unstructured":"Grce M, Davies P, Anttila A et\u00a0al.: Report on the 2007 International workshop on Human papillomaviruses and consensus recommendations for cervical cancer prevention. Cent Eur J Pub Health 16(1), 38\u201340 (2008)","journal-title":"Cent Eur J Pub Health"},{"issue":"Suppl 2","key":"94_CR38","first-page":"7","volume":"31","author":"M Arbyn","year":"2007","unstructured":"Arbyn M, Primix-Zakelj M, Raifu AO et\u00a0al.: The burden of cervical cancer in South-East Europe at the beginning of the 21st century. Coll Antropol 31(Suppl 2), 7\u201310 (2007)","journal-title":"Coll Antropol"},{"issue":"Suppl 2","key":"94_CR39","first-page":"37","volume":"31","author":"A Znaor","year":"2007","unstructured":"Znaor A, Strnad M: Cervical cancer in Croatia; state of the art and possibilities for prevention. Coll Antropol 31(Suppl 2), 37\u201340 (2007)","journal-title":"Coll Antropol"},{"key":"94_CR40","unstructured":"Croatian National Institute of Public Health Zagreb. 1983\u20132006; No. 1\u201329."},{"issue":"suppl 2","key":"94_CR41","first-page":"89","volume":"31","author":"N Milutin-Gasperov","year":"2007","unstructured":"Milutin-Gasperov N, Sabol I, Halec G, Matovina M, Grce M: Retrospective study of the prevalence of high-risk human papilloma viruses among Croatian women. Coll Antropol 31(suppl 2), 89\u201396 (2007)","journal-title":"Coll Antropol"},{"key":"94_CR42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","volume":"111","author":"N Munoz","year":"2004","unstructured":"Munoz N, Bosch FX, Castellsague X et\u00a0al.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111, 278\u2013285 (2004)","journal-title":"Int J Cancer"},{"issue":"S3","key":"94_CR43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.vaccine.2006.05.042","volume":"24","author":"A Batson","year":"2006","unstructured":"Batson A, Meheus F, Brooke S: Chapter 26: innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine 24(S3), 219\u2013225 (2006)","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"94_CR44","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.vaccine.2006.05.116","volume":"24","author":"GP Garnett","year":"2006","unstructured":"Garnett GP, Kim JJ, French K, Goldie SJ: Chapter 21: modeling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24(Suppl 3), S178\u2013S186 (2006)","journal-title":"Vaccine"},{"key":"94_CR45","unstructured":"World Bank Development Data. http:\/\/devedata.worldbank.org\/hnpstats\/query\/default.html ."},{"issue":"8","key":"94_CR46","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","volume":"359","author":"JJ Kim","year":"2008","unstructured":"Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. N Engl J Med 359(8), 821\u2013832 (2008)","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-009-0094-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-009-0094-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-009-0094-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:34:19Z","timestamp":1559417659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-009-0094-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":46,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1007\/s11864-009-0094-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}